What is the clinical evidence from this study?

Study design: Review. Population: Cardiovascular disease and depression. Intervention: Depression screening (PHQ-2 and PHQ-9).

January 22, 2026Open Access

Bridging Cardiac and Mental Health: Screening for Depression in Cardiology Settings

Key Result

The two-step depression screening approach using PHQ-2 followed by PHQ-9 demonstrates optimal sensitivity (83-87%) and specificity (78-92%) for detecting depression in cardiovascular patients.

Structured PICO

Population

Patients with cardiovascular disease (CVD), including post-myocardial infarction and heart failure populations globally

Intervention

Depression screening using a two-step approach (Patient Health Questionnaire-2 [PHQ-2] followed by Patient Health Questionnaire-9 [PHQ-9])

Despite clinical guidelines recommending routine depression screening in cardiology settings, implementation remains inconsistent due to multiple barriers, though a two-step PHQ-2/PHQ-9 approach offers optimal sensitivity and specificity.

Limitations

Majority of studies focus on English-speaking, high-income countries, limiting generalizability to diverse international contexts.
Long-term outcome studies examining the impact of systematic screening programs on cardiovascular events, mortality, and quality of life remain limited.
Optimal screening intervals and populations require better definition.

Abstract

Depression is a highly prevalent comorbidity in patients with cardiovascular disease (CVD), affecting approximately one in five cardiac patients and contributing to adverse cardiovascular outcomes, increased mortality, and reduced quality of life. Despite clinical guidelines from the American Heart Association recommending routine depression screening, implementation remains inconsistent across cardiology settings. This narrative review synthesizes current evidence on depression screening practices in cardiology clinics, examining prevalence, screening tools, and implementation barriers. The prevalence of depression in cardiovascular patients ranges from 15% to 30%, with higher rates observed in post-myocardial infarction and heart failure populations globally. The two-step screening approach using Patient Health Questionnaire-2 (PHQ-2) followed by Patient Health Questionnaire-9 (PHQ-9) demonstrates optimal sensitivity (83-87%) and specificity (78-92%) while minimizing patient burden. Major implementation barriers include time constraints, inadequate workflow integration, insufficient mental health resources, provider knowledge gaps, and patient-level factors, including stigma and poor treatment acceptance. Successful implementation of depression screening in cardiology clinics requires multilevel strategies addressing system, provider, and patient factors through electronic health record integration, standardized protocols, collaborative care models, and stakeholder engagement.

AI에게 질문

Bookmark

View Full Paper